Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis

Autor:	Courtney E. Leik, George P. Vlasuk, Robert E. Swillo, Gwen A. Morgan, Robert G. Schaub, David L. Crandall, Gray D. Shaw, James K. Hennan, Jonathan M. Brooks
Rok vydání:	2006
Předmět:	Bleeding Time Ticlopidine Time Factors Platelet Aggregation Recombinant Fusion Proteins Eptifibatide Pharmacology Dogs Von Willebrand factor Fibrinolytic Agents von Willebrand Factor medicine Animals Platelet Vascular Patency chemistry.chemical_classification biology Dose-Response Relationship Drug business.industry Vascular disease Coronary Thrombosis Hematology Clopidogrel medicine.disease Thrombosis Blockade Disease Models Animal medicine.anatomical_structure chemistry Platelet Glycoprotein GPIb-IX Complex Immunology biology.protein Drug Therapy Combination Glycoprotein business Peptides Platelet Aggregation Inhibitors medicine.drug Artery
Zdroj:	Thrombosis and haemostasis. 95(3)
ISSN:	0340-6245
Popis:	SummaryUnder high shear arterial blood flow von Willebrand Factor (vWF) binds the platelet receptor glycoprotein (GP) Ibα, leading to platelet adhesion, activation and thrombosis. Blockade of vWF-GPIbα interactions by GPG-290 was investigated in a canine model of coronary artery thrombosis alone and in combination with clopidogrel. GPG-290 (100 µg/kg, n=6; 500 µg/kg, n=6) prolonged time to thrombotic occlusion (TTO) to 105±34 and 156±23 (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad96d8ad61c62888000dfe43ff9174c4 https://pubmed.ncbi.nlm.nih.gov/16525575 Zobrazit plný text záznamu